Cocrystal Pharma Inc
COCP
Company Profile
Business description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Contact
19805 North Creek Parkway
BothellWA98011
USAT: +1 877 262-7123
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
11
Stocks News & Analysis
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
stocks
Most popular shares in SMSFs
With data showing the continued rise of SMSFs, we explore the top stock picks of individual investors
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,196.00 | 21.50 | -0.23% |
| CAC 40 | 7,934.26 | 16.26 | 0.21% |
| DAX 40 | 24,387.93 | 146.47 | 0.60% |
| Dow JONES (US) | 46,067.58 | 587.98 | 1.29% |
| FTSE 100 | 9,442.87 | 15.40 | 0.16% |
| HKSE | 25,889.48 | 400.84 | -1.52% |
| NASDAQ | 22,694.61 | 490.18 | 2.21% |
| Nikkei 225 | 48,088.80 | 491.64 | -1.01% |
| NZX 50 Index | 13,268.07 | 83.85 | -0.63% |
| S&P 500 | 6,654.72 | 102.21 | 1.56% |
| S&P/ASX 200 | 8,886.30 | 23.40 | -0.26% |
| SSE Composite Index | 3,889.50 | 7.53 | -0.19% |